The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)

Francesco Graziano

SOC Oncologia

"Ospedali Riuniti Marche Nord

" via Lombroso 61122




Name/email consistency: medium



  • SOC Oncologia, "Ospedali Riuniti Marche Nord, " via Lombroso 61122, Pesaro, Italy. 2011 - 2012
  • Department of Onco-Hematology, Medical Oncology Unit, Azienda Ospedaliera Ospedale San Salvatore, Pesaro, Italy. 2008 - 2010
  • Medical Oncology Unit, Hospital of Pesaro, Pesaro, Italy. 2000 - 2009
  • Medical Oncology Unit, Hospital of Urbino, Via Bonconte da Montefeltro, 61029 Urbino, Italy. 2002 - 2005


  1. High Let-7a MicroRNA Levels in KRAS-Mutated Colorectal Carcinomas May Rescue Anti-EGFR Therapy Effects in Patients with Chemotherapy-Refractory Metastatic Disease. Ruzzo, A., Graziano, F., Vincenzi, B., Canestrari, E., Perrone, G., Galluccio, N., Catalano, V., Loupakis, F., Rabitti, C., Santini, D., Tonini, G., Fiorentini, G., Rossi, D., Falcone, A., Magnani, M. Oncologist (2012) [Pubmed]
  2. Genetic activation of the MET pathway and prognosis of patients with high-risk, radically resected gastric cancer. Graziano, F., Galluccio, N., Lorenzini, P., Ruzzo, A., Canestrari, E., D'Emidio, S., Catalano, V., Sisti, V., Ligorio, C., Andreoni, F., Rulli, E., Di Oto, E., Fiorentini, G., Zingaretti, C., De Nictolis, M., Cappuzzo, F., Magnani, M. J. Clin. Oncol. (2011) [Pubmed]
  3. Genetic modulation of the Let-7 microRNA binding to KRAS 3'-untranslated region and survival of metastatic colorectal cancer patients treated with salvage cetuximab-irinotecan. Graziano, F., Canestrari, E., Loupakis, F., Ruzzo, A., Galluccio, N., Santini, D., Rocchi, M., Vincenzi, B., Salvatore, L., Cremolini, C., Spoto, C., Catalano, V., D'Emidio, S., Giordani, P., Tonini, G., Falcone, A., Magnani, M. Pharmacogenomics J. (2010) [Pubmed]
  4. Host genetic variants in the IGF binding protein-3 impact on survival of patients with advanced gastric cancer treated with palliative chemotherapy. Graziano, F., Ruzzo, A., Canestrari, E., Catalano, V., Santini, D., Galluccio, N., Loupakis, F., Alessandroni, P., Spada, D., Ficarelli, R., Bisonni, R., D'Emidio, S., Vincenzi, B., Angeletti, S., Salvatore, L., Cremolini, C., Tonini, G., Falcone, A., Magnani, M. Pharmacogenomics (2010) [Pubmed]
  5. Variations in the interleukin-1 receptor antagonist gene impact on survival of patients with advanced colorectal cancer. Graziano, F., Ruzzo, A., Canestrari, E., Loupakis, F., Santini, D., Rulli, E., Humar, B., Galluccio, N., Bisonni, R., Floriani, I., Maltese, P., Falcone, A., Tonini, G., Catalano, V., Fontana, A., Giustini, L., Masi, G., Vincenzi, B., Alessandroni, P., Magnani, M. Pharmacogenomics J. (2009) [Pubmed]
  6. Pharmacogenetic profiling for cetuximab plus irinotecan therapy in patients with refractory advanced colorectal cancer. Graziano, F., Ruzzo, A., Loupakis, F., Canestrari, E., Santini, D., Catalano, V., Bisonni, R., Torresi, U., Floriani, I., Schiavon, G., Andreoni, F., Maltese, P., Rulli, E., Humar, B., Falcone, A., Giustini, L., Tonini, G., Fontana, A., Masi, G., Magnani, M. J. Clin. Oncol. (2008) [Pubmed]
  7. Liver-only metastatic colorectal cancer patients and thymidylate synthase polymorphisms for predicting response to 5-fluorouracil-based chemotherapy. Graziano, F., Ruzzo, A., Loupakis, F., Santini, D., Catalano, V., Canestrari, E., Maltese, P., Bisonni, R., Fornaro, L., Baldi, G., Masi, G., Falcone, A., Tonini, G., Giordani, P., Alessandroni, P., Giustini, L., Vincenzi, B., Magnani, M. Br. J. Cancer (2008) [Pubmed]
  8. Methylenetetrahydrofolate reductase 677C/T gene polymorphism, gastric cancer susceptibility and genomic DNA hypomethylation in an at-risk Italian population. Graziano, F., Kawakami, K., Ruzzo, A., Watanabe, G., Santini, D., Pizzagalli, F., Bisonni, R., Mari, D., Floriani, I., Catalano, V., Silva, R., Tonini, G., Torri, V., Giustini, L., Magnani, M. Int. J. Cancer (2006) [Pubmed]
  9. Prognostic role of interleukin-1beta gene and interleukin-1 receptor antagonist gene polymorphisms in patients with advanced gastric cancer. Graziano, F., Ruzzo, A., Santini, D., Humar, B., Tonini, G., Catalano, V., Berardi, R., Pizzagalli, F., Arduini, F., Bearzi, I., Scartozzi, M., Cascinu, S., Testa, E., Ficarelli, R., Magnani, M. J. Clin. Oncol. (2005) [Pubmed]
  10. Combined analysis of E-cadherin gene (CDH1) promoter hypermethylation and E-cadherin protein expression in patients with gastric cancer: implications for treatment with demethylating drugs. Graziano, F., Arduini, F., Ruzzo, A., Mandolesi, A., Bearzi, I., Silva, R., Muretto, P., Testa, E., Mari, D., Magnani, M., Scartozzi, M., Cascinu, S. Ann. Oncol. (2004) [Pubmed]
  11. Prognostic analysis of E-cadherin gene promoter hypermethylation in patients with surgically resected, node-positive, diffuse gastric cancer. Graziano, F., Arduini, F., Ruzzo, A., Bearzi, I., Humar, B., More, H., Silva, R., Muretto, P., Guilford, P., Testa, E., Mari, D., Magnani, M., Cascinu, S. Clin. Cancer Res. (2004) [Pubmed]
  12. Predictive and prognostic role of E-cadherin protein expression in patients with advanced gastric carcinomas treated with palliative chemotherapy. Graziano, F., Mandolesi, A., Ruzzo, A., Bearzi, I., Testa, E., Arduini, F., Silva, R., Muretto, P., Mari, D., Berardi, R., Scartozzi, M., Lai, V., Cascinu, S., Magnani, M. Tumour Biol. (2004) [Pubmed]
  13. Association of thymidylate synthase polymorphisms with gastric cancer susceptibility. Graziano, F., Kawakami, K., Watanabe, G., Ruzzo, A., Humar, B., Santini, D., Catalano, V., Ficarelli, R., Merriman, T., Panunzi, S., Testa, E., Cascinu, S., Bearzi, I., Tonini, G., Magnani, M. Int. J. Cancer (2004) [Pubmed]
  14. Prognostic molecular markers for planning adjuvant chemotherapy trials in Dukes' B colorectal cancer patients: how much evidence is enough?. Graziano, F., Cascinu, S. Ann. Oncol. (2003) [Pubmed]
  15. Screening E-cadherin germline mutations in Italian patients with familial diffuse gastric cancer: an analysis in the District of Urbino, Region Marche, Central Italy. Graziano, F., Ruzzo, A.M., Bearzi, I., Testa, E., Lai, V., Magnani, M. Tumori (2003) [Pubmed]
  16. A phase II study of weekly cisplatin, 6S-stereoisomer leucovorin and fluorouracil as first-line chemotherapy for elderly patients with advanced gastric cancer. Graziano, F., Santini, D., Testa, E., Catalano, V., Beretta, G.D., Mosconi, S., Tonini, G., Lai, V., Labianca, R., Cascinu, S. Br. J. Cancer (2003) [Pubmed]
  17. The role of the E-cadherin gene (CDH1) in diffuse gastric cancer susceptibility: from the laboratory to clinical practice. Graziano, F., Humar, B., Guilford, P. Ann. Oncol. (2003) [Pubmed]
  18. Potential role of levocarnitine supplementation for the treatment of chemotherapy-induced fatigue in non-anaemic cancer patients. Graziano, F., Bisonni, R., Catalano, V., Silva, R., Rovidati, S., Mencarini, E., Ferraro, B., Canestrari, F., Baldelli, A.M., De Gaetano, A., Giordani, P., Testa, E., Lai, V. Br. J. Cancer (2002) [Pubmed]
  19. Potential role and chronology of abnormal expression of the Deleted in Colon Cancer (DCC) and the p53 proteins in the development of gastric cancer. Graziano, F., Cascinu, S., Staccioli, M.P., Catalano, V., Rossi, M.C., Baldelli, A.M., Giordani, P., Muretto, P., Catalano, G. BMC. Cancer (2001) [Pubmed]
  20. A phase II study of weekly docetaxel as salvage chemotherapy for advanced gastric cancer. Graziano, F., Catalano, V., Baldelli, A.M., Giordani, P., Testa, E., Lai, V., Catalano, G., Battelli, N., Cascinu, S. Ann. Oncol. (2000) [Pubmed]
WikiGenes - Universities